Short Report: No Association of Phenotypic ABO Blood Group and Malaria during Pregnancy

Machteld E. Boel,* Marcus J. Rijken, Mupawaij Pimanpanaranak, Naw Lilay Keereecharoen, Stephane Proux, François Nosten, and Rose McGready

Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand; Academic Medical Center, Amsterdam, The Netherlands; Faculty of Tropical Medicine, Mahidol University, Thailand; Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, United Kingdom

Abstract. In a few small studies an association between blood group O and placental malaria has been described. The relationship between blood group and malaria in pregnancy (Plasmodium vivax and Plasmodium falciparum) was analyzed in 1,468 women from three longitudinal cohort studies in which weekly malaria screening was done systematically during pregnancy. One-third of women (447 of 1,468) had at least one malaria infection in pregnancy. The ABO blood group phenotype was not associated with the species of infection, frequency of malaria attacks, symptoms of malaria, hematocrit, or parasitemia during pregnancy.

INTRODUCTION

Only a few studies have addressed the association between the ABO blood group system and malaria during pregnancy. Four studies from Africa (Gabon,1 The Gambia,2 Malawi,3 and Sudan4) were recently reported in a single work (the total number of women studied was 1,516: 378, 198, 647, and 293 women respectively).1 In The Gambia and Malawi, blood group O conferred a higher risk of active placental infection in primipara, but a significantly lower risk in multipara. These findings were not confirmed by the study from Gabon, in which no statistically significant risk of placental parasitemia was observed in any blood group.1 In another study in Sudan no association was found between blood group and active placental infection, which was observed in 18 of 236 women studied.2 We were unable to find any published reports from Asia. We determined the relationship between blood group and malaria (Plasmodium vivax and Plasmodium falciparum) in pregnancy and pregnancy outcome analyzing longitudinal data from three cohort studies in which regular malaria screening was done systematically during pregnancy.

METHODS

On the western border of Thailand, the Shoklo Malaria Research Unit has been conducting weekly antenatal clinics (ANC) since 1986. It has six established clinics that provide antenatal care and three clinics with delivery services for migrant workers and refugee populations from Myanmar. All pregnant women are encouraged to attend ANC on a weekly basis for malaria screening and early diagnosis and treatment, because there is no drug available for intermittent preventive treatment in this area of multi-drug resistant malaria.5

Since the ANC was established three pregnant women cohort studies have been conducted, all with frequent and longitudinal follow-up for malaria screening and routine blood group testing. In all studies exclusion criteria were limited to women who refused to participate in the trial. Two studies commenced enrollment from the first trimester and one study before 24 weeks in the second trimester. The blood group was obtained routinely in the time frame between enrollment and completion of the study. Attached to the ANC clinics were labor and delivery rooms, where women could deliver with trained midwives. Birth weight was measured on electronic Seca scales (accuracy 10 grams) for unit deliveries and with Salter hanging scales (accuracy 50 g) for home deliveries.

Statistical analysis. Data were analyzed using SPSS for Windows version 18.0 (SPSS, Inc., Chicago, IL). In the analysis, women were categorized as "free of malaria" if all the malaria smears done at antenatal visits were negative, including malaria smears of the mother peripheral and placental blood at delivery. Women with a positive malaria smear were categorized into three groups: "P. vivax (only) group" or "P. falciparum (only) group" or both P. falciparum and P. vivax detected during pregnancy. The analysis of malaria in primipara and multipara was separated for the different species as differences with gravida groups and P. vivax have previously been reported.7 Proportions were compared using the χ² test and the Bonferroni correction was applied for multiple comparisons. Birth weight was only used for analysis if the infant was weighed within 1 day after birth.

Laboratory. Blood smears (thin and thick films) were prepared using the Giemsa coloration and were read for 200 parasites per smear. All stages of the parasites were recorded (asexual and gametocytes). The blood group was tested with the agglutination test using IgM antibody cell line G1/2 and A5). The parasites were recorded (asexual and gametocytes). The analysis of malaria smears done at antenatal visits were negative, including malaria smears of the mother peripheral and placental blood at delivery. Women with a positive malaria smear were categorized into three groups: "P. vivax (only) group" or "P. falciparum (only) group" or both P. falciparum and P. vivax detected during pregnancy. The analysis of malaria in primipara and multipara was separated for the different species as differences with gravida groups and P. vivax have previously been reported.7 Proportions were compared using the χ² test and the Bonferroni correction was applied for multiple comparisons. Birth weight was only used for analysis if the infant was weighed within 1 day after birth.

Ethical approval. All studies were approved by the Ethical Committee of the Faculty of Tropical Medicine, Mahidol University Bangkok, Thailand and Oxford Tropical Medicine Ethical Committee, Oxford University, England.

RESULTS

Of the 1,570 women included in the three cohorts 1,468 (93.5%) had a blood group phenotype available: group O was the most prevalent and group AB the least prevalent (Table 1). The 6.5% (102 of 1,570) of women who did not have blood group tested had a lower median number of antenatal visits (12 [1–32] versus 22 [1–41], P < 0.001), and were less likely to have been followed up until delivery (58% [59 of 102] versus 4% [62 of 1,468], P < 0.001) compared with women who were tested. Out of 1,468 women 447 (30.4%) had at least one malaria episode during pregnancy, and there was no significant difference in the proportion of women with malaria in the different blood groups (Table 2). The number of women with uncomplicated P. falciparum hyperparasitemia (eight cases), or severe P. falciparum malaria (one case), were so low that statistical comparisons were not
performed. Of the 54% (793 of 1,570) women who delivered in the Shoklo Malaria Research Unit (SMRU) clinic, 487 (61.4%) placenta samples were available. Only 5 placetas (1.0%) were malaria positive: for blood group O 0.5% (1 of 205), A 0.9% (1 of 110), B 2.2% (3 of 137), and AB none of 35. Of the women who had malaria during pregnancy the proportion infected with different species was not significantly different between blood groups and this non-significant association was maintained when comparing symptomatic malaria infection, the median number of infections of *P. falciparum* or *P. vivax*, the geometric mean maximum parasitemia of *P. falciparum* or *P. vivax*, or the mean hematocrit at the time of *P. falciparum* or *P. vivax* (Table 3).

The proportion of primipara and multipara women with *P. falciparum* or *P. vivax* was not significantly different between blood groups (Table 3). The analysis was repeated for blood group O versus non-O, and blood group A versus non-A, and no significant differences were observed. The birth weight for all blood groups compared with each other, and for blood group O versus non-O, were not significantly different (data not shown).

**DISCUSSION**

This is the first study to examine the relationship between ABO blood group phenotype in women prospectively and actively followed for malaria (*P. falciparum* and *P. vivax*) during pregnancy. There was no indication from this large cohort where nearly one-third of women were diagnosed with malaria during pregnancy. There was no relationship between birth weight for all blood groups compared with each other, and for blood group O versus non-O, were not significantly different (data not shown).

### Table 1

| Year            | Purpose of study                  | Blood group phenotype n (%)         |
|-----------------|-----------------------------------|------------------------------------|
| First cohort*   | 1998–2000 *P. vivax* prevention RCT CQ versus Placebo | O 192 (38.5) | A 113 (22.6) | B 168 (33.7) | AB 26 (5.2) | total 499 (100.0) |
| Second cohort   | 2007–2009 Post-partum malaria susceptibility | O 293 (38.9) | A 179 (23.7) | B 230 (30.5) | AB 52 (6.9) | total 754 (100.0) |
| Third cohort    | 2009–2011 Impact of MIP on fetal growth | O 96 (44.7) | A 50 (23.3) | B 54 (25.1) | AB 15 (7.0) | total 215 (100.0) |
| Total           |                                   | O 581 (39.6) | A 342 (23.3) | B 452 (30.8) | AB 93 (6.3) | total 1468 (100.0) |

*One thousand women recruited but only the placebo group was included here.10 CQ = chloroquine, MIP = malaria in pregnancy, RCT = randomized controlled trial.

### Table 2

| ABO blood group phenotype | O | A | B | AB | P value* |
|--------------------------|---|---|---|----|---------|
| Any malaria              |   |   |   |    |         |
| No Malaria               | 408 (70.2) | 239 (69.9) | 314 (69.5) | 60 (64.5) | NS |
| Malaria                  | 173 (29.8) | 103 (30.1) | 138 (30.5) | 33 (35.5) | NS |
| Species of malaria       |   |   |   |    |         |
| *P. falciparum* only     | 31 (17.9) | 20 (19.4) | 25 (18.1) | 3 (9.1) | NS |
| *P. vivax* only          | 99 (57.2) | 55 (53.5) | 81 (58.7) | 20 (60.0) | NS |
| Both *P. falciparum* and *P. vivax* | 43 (24.9) | 28 (27.2) | 32 (23.2) | 10 (30.3) | NS |
| Symptomatic malaria (at least once) |   |   |   |    |         |
| Asymptomatic             | 74 (43.0) | 46 (44.7) | 50 (36.2) | 14 (42.4) | NS |
| Symptomatic              | 98 (57.0) | 57 (55.3) | 88 (63.8) | 19 (57.6) | NS |
| Median number of infections/pregnancy |   |   |   |    |         |
| *P. falciparum* episodes | 1 [1–4] | 1 [1–3] | 1 [1–4] | 1 [1–3] | NS |
| *P. vivax* episodes      | 2 [1–6] | 2 [1–7] | 2 [1–6] | 1 [1–6] | NS |
| Geometric mean parasitemia/uL |   |   |   |    |         |
| *P. falciparum*          | 3,759 [16–194,805] | 1,952 [16–915,588] | 5,373 [32–311,458] | 2,349 [112–74611] | NS |
| *P. vivax*               | 314 [16–62,734] | 239 [16–41,448] | 374 [16–41,448] | 380 [16–49,739] | NS |
| Mean hematocrit, %       |   |   |   |    |         |
| *P. falciparum*          | 30 [17–39] | 32 [24–44] | 31 [23–44] | 30 [21–46] | NS |
| *P. vivax*               | 32 [17–45] | 31 [34–45] | 31 [19–39] | 32 [17–45] | NS |

*Bonferroni corrected; NS = non-significant.
placental malaria an increased birth weight and a higher ponderal index were found in neonates from women with blood group O.2,3

This cohort is likely to be less subject to bias than previous publications as pregnant women were followed longitudinally and actively; therefore, the diagnosis of malaria did not depend upon whether a placenta was available or not. Despite the large number of women some of the sub-group analysis, especially for blood group AB, had only a small number of women. A much larger cohort from this population would be required to definitively rule out differences with blood group AB. This study does not support an association between blood group and malaria during pregnancy.

Acknowledgments: We thank the women who agreed to participate in these studies. We acknowledge the midwives, medics, laboratory and logistics personnel who worked to make the study possible.

Financial support: This study was funded by the Wellcome Trust, which is a UK-based medical research charity and is independent from all drug companies. It has no financial links with the manufacturers of the diagnostic tests or the drugs that were used in this study.

Authors’ addresses: Machteld E. Boel, Marcus J. Rijken, Mupawjay Pimapanararak, Naw Lily Keereecharoen, and Stephane Proux, Shoklo Malaria Research Unit (SMRU), Mae Sot, Tak, Thailand; Machteld E. Boel, Marcus J. Rijken, Mupawjay Pimapanararak, Naw Lily Keereecharoen, and Stephane Proux, Shoklo Malaria Research Unit (SMRU), Mae Sot, Tak, Thailand, E-mails: machteld@shoklo-unit.com, marcus@shoklo-unit.com, ehmoosmru@gmail.com, malariaokters@gmail.com, and steph@shoklo-unit.com. Francois Nosten and Rose McGready, Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; and Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, UK, E-mails: francois@tropmedres.ac and rose@shoklo-unit.com.

REFERENCES

1. Adegnika AA, Luty AJ, Grobusch MP, Ramharter M, Yazdanaksh M, Kremsner PG, Schwarz NG, 2011. ABO blood group and the risk of placental malaria in sub-Saharan Africa. Malar J 10: 101.

2. Loscertales MP, Brabin BJ, 2006. ABO phenotypes and malaria related outcomes in mothers and babies in The Gambia: a role for histo-blood groups in placental malaria? Malar J 5: 72.

3. Senga E, Loscertales MP, Makwakwa KE, Liomba GN, Dzamalala C, Kazembe PN, Brabin BJ, 2007. ABO blood group phenotypes influence parity specific immunity to Plasmodium falciparum malaria in Malawian women. Malar J 6: 102.

4. Adam I, Babiker S, Mohmmed AA, Salih MM, Zaki ZM, 2007. ABO blood group system and placental malaria in an area of unstable malaria transmission in eastern Sudan. Malar J 6: 110.

5. Adam I, Adamt GK, Mohmmed AA, Salih MM, Ibrahuim SA, Ryan CA, 2009. Placental malaria and lack of prenatal care in an area of unstable malaria transmission in eastern Sudan. J Parasitol 95: 751–752.

6. McGready R, Tan SO, Ashley EA, Pimapanararak M, Viladpai-Nguyen J, Phaihphun L, Wustefeld K, Barens M, Laochan N, Keereecharoen L, Lindegardh N, Singhasivanon P, White NJ, Nosten F, 2008. A randomized controlled trial of artether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med 5: e253.

7. Nosten F, ter Kuile F, Maelankirri L, Decludt B, White NJ, 1991. Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg 85: 424–429.

8. McGready R, Davison BB, Stepniwksa K, Cho T, Shee H, Brockman A, Udomsangpetch R, Looaressawan S, White NJ, Meshnick SR, Nosten F, 2004. The effects of Plasmodium falciparum and P. vivax infections on placental histopathology in an area of low malaria transmission. Am J Trop Med Hyg 70: 398–407.

9. Rijken MJ, McGready R, Boel ME, Poepoprodjo R, Singh N, Syafuddin D, Rogerson S, Nosten F, 2012. Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis 12: 75–88.

10. Villegas L, McGready R, Htway M, Paw MK, Pimapanararak M, Arunjerda R, Viladpai-Nguyen SJ, Greenwood B, White NJ, Nosten F, 2007. Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial. Trop Med Int Health 12: 209–218.